Cell-free DNA and RNA in plasma as new tools for molecular diagnostics

References

• Mandel P, Metais P Les acides nucleiques du plasma sanguin chez l'Homme. CR Acad. Sc]. Paris 142,241–243 (1948).
   Google Scholar
• Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. j Clin. Invest. 45(11), 1732–1740 (1966).
   Google Scholar
• Leon SA, Shapiro B, SIdaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37(3), 646–650 (1977).
   Google Scholar
• Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5), 318–322 (1989).
   PubMed Web of Science ®Google Scholar
• Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers PIE% 3(1), 67–71 (1994).
   PubMed Web of Science ®Google Scholar
• ••One of the earliest studies to demonstratethe existence of tumor-specific DNA sequences in the plasma of cancer patients.
   Google Scholar
• Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-Rasgene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. BE j 1-Lematol 86(4), 774–779 (1994).
   Google Scholar
• Sorenson GD. Detection of mutated K-Ras2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6(6), 2129–2137 (2000).
   Google Scholar
• Dianxu F, Shengdao Z, Tianquan H etal A prospective study of detection of pancreatic carcinoma by combined plasma K-Ras mutations and serum CA19-9 analysis. Pancreas 25 (4), 336–341 (2002).
   Google Scholar
• Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-Ras mutations with the use of plasma DNA. j Natl Cancer Inst. 92(11), 918–923 (2000).
   Google Scholar
• Castells A, Puig P, Mora J eta]. K-Ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. j Clin. 017COI 17(2), 578–584 (1999).
   Google Scholar
• Ryan BM, Lefort F, McManus R etal A prospective study of circulating mutant K-Ras2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow-up. Gut52(1), 101–108 (2003).
   Google Scholar
• Chen XQ, Stroun M, Magnenat JL eta]. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med. 2(9), 1033–1035 (1996).
   PubMedGoogle Scholar
• •One of the earliest studies to demonstrate the presence of circulating microsatellite alterations in cancer patients.
   Google Scholar
• Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med. 2 (9), 1035–1037 (1996).
   PubMed Web of Science ®Google Scholar
• •One of the earliest studies to demonstrate the presence of circulating microsatellite alterations in cancer patients.
   Google Scholar
• Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5(10), 2689–2692 (1999).
   PubMed Web of Science ®Google Scholar
• Taback B, Giuliano AE, Hansen NM, Hoon DS. Microsatellite alterations detected in the serum of early stage breast cancer patients. Ann. NY Acad. Sc]. 945, 22–30 (2001).
   PubMed Web of Science ®Google Scholar
• Silva JM, Silva J, Sanchez A etal Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8(12), 3761–3766 (2002).
   PubMed Web of Science ®Google Scholar
• Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67–70 (1999).
   Google Scholar
• Wong IH, Lo YMD, Zhang J etal Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59(1), 71–73 (1999).
   Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L etal Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4), 892–895 (2000).
   Google Scholar
• Lee TL, Leung WK, Chan MW eta]. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res. 8(6), 1761–1766 (2002).
   Google Scholar
• Chang HW, Chan A, Kwong DL, Wei WI, Sham JS, Yuen AP. Detection of hypermethylated R1Z1 gene in primary tumor, mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient. Clin. Cancer Res. 9(3), 1033–1038 (2003).
   Google Scholar
• Kawakami K, Brabender J, Lord RV etal Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. j Natl Cancer Inst. 92(22), 1805–1811 (2000).
   Google Scholar
• Zhong S, Ng MC, Lo YMD, Chan JC, Johnson PJ. Presence of mitochondrial tRNA(Leu[UUR1) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus. Clin. Pathol 53(6), 466–469 (2000).
   Google Scholar
• Jeronimo C, Nomoto S, Caballero OL etal. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20(37), 5195–5198 (2001).
   PubMedGoogle Scholar
• Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin. Cancer Res. 8(2), 481–487 (2002).
   Google Scholar
• Capone RB, Pai SI, Koch WM etal Detection and quantitation of human papilloma virus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6(11), 4171–4175 (2000).
   PubMed Web of Science ®Google Scholar
• Pornthanakasem W Shotelersuk K, Termrungruanglert W, Voravud N, Niruthisard S, Mutirangura A. Human papilloma virus DNA in plasma of patients with cervical cancer. BMC Cancer1(1), 2 (2001).
   PubMedGoogle Scholar
• Mutirangura A, Pornthanakasem W, Theamboonlers A etal Epstein—Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin. Cancer Res. 4(3), 665–669 (1998).
   PubMedGoogle Scholar
• Lo YMD, Chan LYS, Lo KW et a/. Quantitative analysis of cell-free Epstein—Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59(6), 1188–1191 (1999).
   PubMedGoogle Scholar
• •Describes the application of real-time quantitative PCR for the measurement of Epstein-Barr virus DNA concentrations in the plasma of nasopharyngeal carcinoma patients.
   Google Scholar
• Lo YMD, Leung SF, Chan LYS eta]. Kinetics of plasma Epstein—Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 60(9), 2351–2355 (2000).
   PubMedGoogle Scholar
• Lo YMD, Chan LYS, Chan AT etal Quantitative and temporal correlation between circulating cell-free Epstein—Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59(21), 5452–5455 (1999).
   Google Scholar
• Lo YMD, Chan AT, Chan LYS eta]. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein—Barr virus DNA. Cancer Res. 60 (24), 6878–6881 (2000).
   PubMed Web of Science ®Google Scholar
• Chan AT, Lo YMD, Zee B et al Plasma Epstein—Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. .1. Natl Cancer Inst. 94 (21), 1614–1619 (2002).
   Google Scholar
• Lo YMD, Chan WY, Ng EKO etal. Circulating Epstein—Barr virus DNA in the serum of patients with gastric carcinoma. Clin. Cancer Res. 7(7), 1856–1859 (2001).
   Google Scholar
• Gallagher A, Armstrong AA, MacKenzie J et al Detection of Epstein—Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. int. Cancer84(4), 442–448 (1999).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Huang ML, Atienza EE, Ferrenberg JM, Corey L. Detection of Epstein—Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Clin. Microbial 37(4), 1113–1116 (1999).
   Google Scholar
• Stevens SJ, Vervoort MB, van den Brule AJ, Meenhorst PL, Meijer CJ, Middeldorp JM. Monitoring of Epstein—Barr virus DNA load in peripheral blood by quantitative competitive PCR. j Clin. Microbial 37(9), 2852–2857 (1999).
   Google Scholar
• Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YMD. Diagnostic and prognostic implications of circulating cell-free Epstein—Barr virus DNA in natural killer/T-cell lymphoma. Clin. Cancer Res. 8(1), 29–34 (2002).
   Google Scholar
• Lo YMD, Corbetta N, Chamberlain PP et al Presence of fetal DNA in maternal plasma and serum. Lancet350(9076), 485–487 (1997).
   PubMed Web of Science ®Google Scholar
• ••Reports the discovery of fetal DNA inmaternal plasma.
   Google Scholar
• Lo YMD, Tein MS, Lau TK et al Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. 4in.j Hum. Genet. 62 (4), 768–775 (1998).
   Google Scholar
• •Describes the application of real-time quantitative PCR for the measurement of fetal DNA concentration in maternal plasma and provides a strong basis for the diagnosis of pregnancy-associated complications related to quantitative abnormalities of circulating fetal DNA.
   Google Scholar
• Sekizawa A, Kondo T, Iwasaki M etal Accuracy of fetal gender determination by analysis of DNA in maternal plasma. Clin. Chem. 47(10), 1856–1858 (2001).
   PubMedGoogle Scholar
• Wei C, Saller DN, Sutherland JW. Detection and quantification by homogeneous PCR of cell-free fetal DNA in maternal plasma. Clin. Chem. 47(2), 336–338 (2001).
   Google Scholar
• Honda H, Miharu N, Ohashi Y et al Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum. Genet. 110(1), 75–79 (2002).
   PubMedGoogle Scholar
• Rijnders RJ, van der Schoot CE, Bossers B, de Vroede MA, Christiaens GC. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet. Gynecol 98(3), 374–378 (2001).
   PubMedGoogle Scholar
• Faas BH, Beuling EA, Christiaens GC, von dem Borne AE, van der Schoot CE. Detection of fetal RhD-specific sequences in maternal plasma. Lancet 352(9135), 1196 (1998).
   PubMedGoogle Scholar
• Lo YMD, Hjelm NM, Fidler C eta]. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N. Engl. Merl 339(24), 1734–1738 (1998).
   Google Scholar
• Zhong XY, Holzgreve W, Hahn S. Risk-free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell-free fetal DNA in maternal plasma. Swiss Merl Wkly131(5-6), 70–74 (2001).
   PubMedGoogle Scholar
• Tang NL, Leung TN, Zhang J, Lau TK, Lo YMD. Detection of fetal-derived paternally inherited X-chromosome polymorphisms in maternal plasma. Clin. Chem. 45(11), 2033–2035 (1999).
   Google Scholar
• •Beyond the detection of Y chromosomal sequences, this paper describes a new diagnostic approach for the analysis of female fetal DNA in maternal plasma.
   Google Scholar
• Chen CP, Chem SR, Wang W Fetal DNA in maternal plasma: the prenatal detection of a paternally inherited fetal aneuploidy. Prenat. Diagn. 20(4), 355–357 (2000).
   PubMedGoogle Scholar
• Amicucci P, Gennarelli M, Novelli G, Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin. Chem. 46(2), 301–302 (2000).
   PubMed Web of Science ®Google Scholar
• Chiu RWK, Lau TK, Gong ZQ, Cheung PT, Leung TN, Lo YMD. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia through the use of fetal DNA in maternal plasma. A117. Hum. Genet. 65(4S), 666 (2001).
   Google Scholar
• Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YMD. Maternal plasma fetal DNA as a marker for preterm labour. Lancet352(9144), 1904–1905 (1998).
   PubMed Web of Science ®Google Scholar
• Lo YMD, Leung TN, Tein MS eta]. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin. Chem. 45(2), 184–188 (1999).
   Google Scholar
• Leung TN, Zhang J, Lau TK, Chan LYS, Lo YMD. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin. Chem. 47(1), 137–139 (2001).
   Google Scholar
• Sekizawa A, Jimbo M, Saito H eta]. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am. .1. Obstet. Gynecol 188(2), 480–484 (2003).
   Google Scholar
• Byrne BM, Crowley A, Taulo F, Anthony J, O'Leary JJ, O'Herlihy C. Fetal DNA quantitation in peripheral blood is not useful as a marker of disease severity in women with preeclampsia. Hypertens. Pirgnancy22(2), 157-164(2003).
   Google Scholar
• Caramelli E, Rizzo N, Concu M eta]. Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction: a pilot study. Pmnat. Diagn. 23(5), 367-371(2003).
   Google Scholar
• Lo YMD, Lau TK, Zhang J etal Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin. Chem. 45 (10), 1747–1751 (1999).
   Google Scholar
• Farina A, LeShane ES, Lambert-Messerlian GM eta]. Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down's syndrome pregnancy. Clin. Chem. 49(2), 239–242 (2003).
   Google Scholar
• Wataganara T, LeShane ES, Farina A eta]. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum. Genet. 112(2), 204–208 (2003).
   Google Scholar
• Lo YMD, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 351(9112), 1329–1330 (1998).
   PubMed Web of Science ®Google Scholar
• Lui YYN, Chik KW, Chiu RVVK, Ho CY, Lam CW, Lo YMD. Predominant hematopoietic origin of cell-free DNA in Plasma and serum after sex-mismatched bone marrow transplantation. Clin. Chem. 48(3), 421–427 (2002).
   PubMed Web of Science ®Google Scholar
• Lui YYN, Woo KS, Wang AY eta]. Origin of plasma cell-free DNA after solid organ transplantation. Clin. Chem. 49(3), 495–496 (2003).
   Google Scholar
• Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin. Chem. 46(3), 319–323 (2000).
   Google Scholar
• Rainer TH, Wong LK, Lam W etal Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin. Chem. 49(4), 562–569 (2003).
   PubMed Web of Science ®Google Scholar
• Rogers JC, Boldt D, Kornfeld S, Skinner A, Valeri CR. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen. Pmc. Natl Acad. Sc] USA 69(7), 1685–1689 (1972).
   Google Scholar
• Fournie GJ, Lambert PH, Meischer PA. Release of DNA in circulating blood and induction of antiDNA antibodies after injection of bacterial lipopolysaccharides. J. Exp. Merl 140(5), 1189–1206 (1974).
   Google Scholar
• Fournie GJ, Courtin JP, Laval F et al Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett. 91(2), 221–227 (1995).
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1), 89–97 (1998).
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S etal DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659–1665 (2001).
   Google Scholar
• ••The biology of release of free circulatingDNA was investigated in this study, which finds that the characteristics of plasma DNA from cancer patients are similar to those in DNA from dying cells.
   Google Scholar
• Chan KCA, Zhang J, Chan AT etal Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res. 63(9), 2028–2032 (2003).
   Google Scholar
• Kolialexi A, Tsangaris GT, Antsaldis A etal. Apoptosis in maternal peripheral blood during pregnancy. Fetal Diagn. Thet: 16(1), 32–37 (2001).
   Google Scholar
• Ng EKO, Tsui NBY, Lau TK eta]. From the cover: mRNA of placental origin is readily detectable in maternal plasma. Proc. Natl Acad. Sc]. USA 100(8), 4748–4753 (2003).
   Google Scholar
• ••Shows that placenta-expressed mRNAcan be used as a gender- and polymorphism-independent fetal RNA marker in maternal plasma for noninvasive prenatal diagnosis.
   Google Scholar
• Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am. J Obstet. Gynecol 186(1), 158–166 (2002).
   Google Scholar
• Sekizawa A, Yokokawa K, Sugito Y et al Evaluation of bidirectional transfer of plasma DNA through placenta. Hum. Genet. 113(4), 307–310 (2003).
   PubMedGoogle Scholar
• Lo YMD, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am. Hum. Genet. 64(1), 218–224 (1999).
   Google Scholar
• •Demonstrates the rapid turnover of fetal DNA from maternal plasma with a mean apparent half-life of 16.3 min.
   Google Scholar
• Invernizzi P, Battezzati PM, Podda M, Simoni G. Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. Hum. Genet. 111(6), 576 (2002).
   PubMed Web of Science ®Google Scholar
• Smid M, Galbiati S, Vassallo A et al No evidence of fetal DNA persistence in maternal plasma after pregnancy. Hum. Genet. 112(5-6), 617–618 (2003).
   PubMedGoogle Scholar
• Benachi A, Steffann J, Gautier E etal Fetal DNA in maternal serum: does it persist after pregnancy? Hum. Genet 113(1), 76–79 (2003).
   Google Scholar
• Botezatu I, Serdyuk 0, Potapova G et al Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46(8 Pt 1), 1078–1084 (2000).
   Google Scholar
• Lo KW, Lo YMD, Leung SF et al Analysis of cell-free Epstein—Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin. Chem. 45(8 Pt 1), 1292-1294(1999).
   Google Scholar
• ••One of the earliest studies to demonstratethe presence of tumor-derived mRNA in the plasma of cancer patients.
   Google Scholar
• Kopreski MS, Benko FA, Kwak LW Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res.5(8), 1961–1965 (1999).
   Google Scholar
• ••One of the earliest studies to demonstratethe presence of tumor-derived mRNA in the plasma of cancer patients.
   Google Scholar
• Chen XQ, Bonnefoi H, Pelte MF et al Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 6(10), 3823–3826 (2000).
   PubMed Web of Science ®Google Scholar
• Miura N, Shiota G, Nakagawa T etal Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology 64 (4), 430–434 (2003) .
   PubMedGoogle Scholar
• Dasi F, Lledo S, Garcia-Granero E etal Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab. Invest. 81(5), 767–769 (2001).
   PubMedGoogle Scholar
• Kairat A, Beerheide W, Zhou G, Tang ZY, Edler L, Schroder CH. Truncated hepatitis B virus RNA in human hepatocellular carcinoma: its representation in patients with advancing age. Intervirology42(4), 228–237 (1999).
   PubMedGoogle Scholar
• Su Q, Wang SF, Chang TE etal Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin. Cancer Res. 7(7), 2005–2015 (2001).
   PubMedGoogle Scholar
• Breitkreutz R, Zhang W, Lee M et al Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HB carriers with hepatocellular carcinoma. Ann. NY Acad. Sci 945,195–206 (2001).
   PubMedGoogle Scholar
• Poon LL, Leung TN, Lau TK, Lo YMD. Presence of fetal RNA in maternal plasma. Clin. Chem. 46(11), 1832–1834 (2000).
   PubMed Web of Science ®Google Scholar
• ••Reports the discovery of fetal RNA inmaternal plasma.
   Google Scholar
• Ng EKO, Leung TN, Tsui NBY etal The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin. Chem. 49(5), 727–731 (2003).
   PubMedGoogle Scholar
• Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp. Cell Res. 260(2), 248–256 (2000).
   Google Scholar
• Hasselmann DO, Rappl G, Tilgen W Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin. Chem. 47(8), 1488–1489 (2001).
   Google Scholar
• Ng EKO, Tsui NBY, Lam NYL et a/. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin. Chem. 48(8), 1212–1217 (2002).
   Google Scholar
• •Demonstrates the presence of particle-associated RNA species in plasma, which may provide one explanation for the inherent stability of free circulating RNA.
   Google Scholar
• Chiu RVVK, Poon LL, Lau TK, Leung TN, Wong EM, Lo YMD. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin. Chem. 47 (9), 1607–1613 (2001).
   PubMed Web of Science ®Google Scholar
• Lo YMD, Lau TK, Chan LYS, Leung TN, Chang AM. Quantitative analysis of the bidirectional fetomaternal transfer of nucleated cells and plasma DNA. Clin. Chem. 46(9), 1301–1309 (2000).
   Google Scholar
• Fetal Genotyping Service www.bloodnet.nbs.nhs.uldibgrl/Reference %20Services/RefSer_genotyping.htm (Viewed October 2003)
   Google Scholar